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There are many important prognostic factors in advanced stage cervical cancer 
primary treated with radiotherapy.  Besides clinical factors, many biomarkers have 
been studied in relation with radiotherapy response. The p70s6k is a biomarker 
which plays a significant role in cell proliferation. Increased levels of p70s6k are 
also associated with drug resistance in cancer. In the present study, the relationship 
between the expression level of p70s6k before treatment and the radiotherapy 
response in cervical cancer was determined. Immunohistochemical staining of 
p70s6k, MIB-1, and p53 was conducted in microscopic slide from 21 cancer tissue 
biopsies before treatment with radiotherapy. After the treatment had completed 
early radiotherapy response was observed by pelvic control method. The results 
showed that p70s6k is partly highly expressed (61.9%, 13/21) and partly low 
expressed (38.1%, 8/21) in the cancer cells. They also show that there is no 
statistically significant differences on AgNOR mean, MIB-1, and p53 indices in the 
different degrees of p70s6k expression (p≥0.05). Higher expression levels of p70s6k 
is more strongly associated with good radiotherapy response compared to lower 
ones (p=0.05). In conclusion, the level of p70s6k expression before treatment has an 
association with radiotherapy response. 
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INTRODUCTION 
 
Cervical cancer is the most frequently found 
malignancy disease in Indonesia. Usually, patients 
come to the hospital when already at a locally-
advanced stage. One of the treatment choices                 
in locally-advanced form of this cancer is 
radiotherapy. This treatment could sometimes be 
combined with chemotherapy, resulting in what is 
known as concurrent chemoradiotherapy [1,2]. 
There are many important prognostic factors 
in advanced-stage cervical cancer that are primarily 
treated with chemoradiotherapy, such as clinical 
pathologic factors, including stage and tumor 
histology [3]. Besides the clinical pathologic 
factors, many biomarkers have been studied in 
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relation to the patient’s survival and/or response               
to chemoradiotherapy. Biomarkers are biological 
molecules in body fluids or tissues that are 
quantitatively measured and evaluated as indicators 
of normal biological processes, pathogenesis,                 
or pharmacologic response to a therapeutic 
intervention [4]. Clearly response to 
chemoradiotherapy as a part of therapeutic 
intervention can also be predicted by measuring 
some biomarkesr. At present, the focus of 
improving survival rates is mainly on targeted 
therapies in combination with standard 
chemoradiotherapy [5]. 
The p70s6k is a serine/threonine protein 
kinase responsible for the phosphorylation and 
activation of 40S ribosomal subunit protein S6 [6]. 
It acts downstream of the mammalian target of 
rapamycin (mTOR) in Akt pathway. The activation 
target of p70s6k and its downstream are ribosomal 
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protein S6 mediates nutrient and mitogen-stimulated 
translation, which is essential for cell growth and 
proliferation [7]. In some in vitro studies, it was 
found that activity of p70s6k is related to the 
prevention of apoptosis as one of the death 
processes in cancer cell treatment with radiotherapy 
that can be induced with intrinsic or extrinsic DNA 
damage [8,9].  
Nucleolar organizer regions (NORs) are 
chromosomal segments that carry ribosomal genes. 
Silver-stained NORs are called AgNORs and when 
examined using light microscopy they appear as 
well-defined black dots which are exclusively 
located within the nucleoli [10]. The MIB-1 is a 
monoclonal antibody to detect Ki-67 antigen. This 
antigen can be detected in the nuclei of cells during 
the gap1 (G1), synthesis (S), gap2 (G2), and mitosis 
(M) phases of the cell cycle. Thus, it can only be 
detected in the nuclei of proliferating cells in all 
active phases of the cell-division cycle, but is absent 
in non-proliferating cells [11]. The p53 gene, 
located on chromosome 17, encodes a 53-kDa 
protein. The wild-type p53 protein is a transcription 
factor that, when activated, acts to arrest cells 
temporarily in the G1/G2 phase of the cell cycle, 
thus allowing time for the repair of the damaged 
DNA, or to cause cells to proceed to apoptosis if the 
DNA damage is irreparable [12]. 
Our previous publications reported a 
correlation between apoptosis caspase-3 and better 
radiotherapy response. However, the high level of 
Akt indicated poor radiotherapy response, and there 
were no association between some proliferation 
markers like AgNOR, MIB-1, and p53 with 
radiotherapy response [13,14]. The aim of the 
present study is to investigate the relationship 
between p70s6k as biomarker and radiotherapy 
response in cervical cancer. 
 
 
EXPERIMENTAL METHODS 
 
Patients 
 
Twenty one consecutive patients who have 
undergone complete treatments, from a whole series 
of 60 cases who suffered from non-metastatic 
localized cervical carcinoma in local advance stage 
(IIB-IIIB), were prospectively conducted from July 
2010 to March 2011. All the 60 patients satisfied the 
inclusion criteria but did not complete biopsy and 
clinical data. All the 21 chosen patients were 
diagnosed and treated by definitive concurrent 
chemoradiotherapy in the Cipto Mangunkusumo 
and Hasan Sadikin Hospitals. The radiation therapy 
treatment conducted included external and internal 
radiation, namely external beam radiotherapy 
(EBRT) using Co-60 with a total dose of 50 Gy               
in 25 fractions and internal radiation with 
192
Ir high 
dose-rate intracavitary brachytherapy (HDR-ICBT) 
using a microSelectron (Nucletron International, 
Amsterdam, Netherlands) followed by EBRT in                
two fractions (850 cGy/fraction). Cisplatin as a 
chemoradiotherapic agent was administered at a 
dose of 40 mg/m
2
 on days 1, 8, 15, 22, and 29;                 
it was given concurrently with the EBRT in 2 hours 
or less before the treatment for the corresponding 
day. The process of diagnosis and treatment 
followed the Standard Operation Procedure (SOP) 
as shown in our previous publication [13]. 
Before the studies were carried out, the 
research proposal was approved by the Health 
Research Ethics Committee, Faculty of Medicine, 
University of Indonesia, and the patients received 
written informed consent document.  
 
 
Radiotherapy Response 
 
Tumor response to radiation therapy was 
evaluated by radiotherapists by pelvic control [15]: 
1. NRT (no gross residual tumor) response as good 
response is a complete or nearly complete 
regression of pelvic tumor, non-specific fibrosis, 
or granulation over the cervix. 
2. GT (gross residual tumor) response as a bad 
response is gross tumor or palpable nodularity on 
cervix, and/or palpable in duration on the 
parametrium. 
 
 
AgNOR and Immunohistochemistry 
 
AgNOR staining (silver staining) and 
immunohistochemistry of MIB-1, p53, and p70s6k 
were performed on microscopic slides obtained 
from cancer tissue biopsy before treatment with 
radiotherapy. A simple silver staining technique was 
performed in accordance with the technique 
described by Ploton et al. [16]. Tissue sections,               
4 m thick, were cut from formalin fixed, paraffin-
wax embedded blocks. The sections were dewaxed 
in xylene and then hydrated through decreasing 
grades of ethanol followed by washing in deionized 
water for 8-10 minutes. The staining solution was 
prepared by dissolution of powdered gelatin with 
concentration of 2% w/v in deionized water over 
water bath at 60-70°C. Pure formic acid was then 
added to a final concentration of 1%. This solution 
was mixed 1:2(v/v) with 50% aqueous silver nitrate 
solution (freshly made each time), filtered through  
a 0.22 mm Millipore filter, and dropped onto the 
slide-mounted section. The sections were incubated 
in the dark for 40-45 minutes at room temperature. 
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After rinsing three times with deionized water,              
the slides were immersed for 10 minutes in 5% 
sodium thiosulphate solution, dehydrated in 
ascending ethanol concentrations, cleared with 
xylene, and mounted.  
In immunohistochemistry, after dewaxing 
process as in AgNOR staining, tissue sections were 
washed with phosphate-buffered saline (PBS) three 
times (5 minutes each). The sections were incubated 
in Dako Target Retrieval Buffer (pH 6: 
DakoCytomation, Denmark) in a microwave oven at 
94°C for 20 minutes, cooled to room temperature 
for 20 minutes, and washed in PBS (3 times for 5 
minutes each). Then, the sections were incubated 
with Dako Peroxidase Block (DakoCytomation) for 
10 minutes, followed by PBS for 10 minutes, and 
incubation with anti p70s6k, MIB-1 and anti-p53 
antibodies, overnight at 4°C. After incubation with 
antibodies, the sections were washed with PBS for 
15 minutes, and incubated with secondary antibody 
(Labeled Polymer HRP from DakoCytomation) for 
60 minutes at room temperature. Then, the sections 
were washed with PBS for 10 minutes, developed 
with 3,3'-diaminobenzidine tetrahydrochloride for 
30 seconds, slightly counterstained with 
hematoxylin, dehydrated, and mounted; this 
technique was done with some modifications  from 
the original method [17]. p70s6k expression is 
observed in the nucleus and cell cytoplasm. The 
degree of its expression was estimated blindly to the 
clinical patient characteristics and outcome, using 
microscope magnification (10×40) semi-
quantitatively. The scores were from negative (−) to 
slightly positive (+), moderately positive (++) and 
strongly positive (+++). [18]. The scores from 
negative to slightly positive were grouped as “low 
expression” (1) while moderate to strong positive 
was grouped as “high expression.” 
 
 
Statistical Analysis 
Analysis of variance (ANOVA) test was used 
in the comparison between expression of p70s6k 
and AgNOR mean, MIB-1 index and p53 index 
before treatment. Fisher Exact Test was used in the 
comparison between expressions of p70s6k with 
radiotherapy response. All tests used p≤0.05 as 
statistical significance criterion. Minitab 17 was 
used for data analysis. 
 
 
RESULTS AND DISCUSSION 
 
The expression of p70s6k was identified as 
brown color in the nuclei and cytoplasm of cancer 
cells as shown in Figs. 1 (a) and 1 (b) (with the    
blue arrow). Its expression was observed in all of 
the 21 microscopic slides from cancer tissue      
slides before radiotherapy. Then, they can be 
classified into two groups, namely the High 
Expression of p70s6k group (61.9%, 13/21) or also 
classified as 2, and Low Expression of p70s6k 
group (38.1%, 8/21), or also classified as 1; this is 
shown in Fig. 2 and Fig. 3 (those two groups will 
afterwards be also simply referred to as “High 
Expression” and “Low Expression”, respectively). 
Table 1 shows that between the two groups       
(High Expression vs. Low Expression) there is no 
statistically significant difference in AgNOR    
mean, MIB-1, and p53 index. In contrast to the 
AgNOR mean that tends to be lower in                  
the High Expression group, both MIB-1 and        
p53 index appear to be higher in the High 
Expression group than in the Low Expression    
group (Fig. 2 a,b,c). After radiotherapy, however, 
there were statistically significant differences          
in the proportions of complete and partial 
radiotherapy responses between the High and      
Low Expression of p70s6k groups  at p=0.05, as      
shown in Fig. 3. 
 
 
 
(a) 
 
 
(b) 
 
Fig 1. Expression of  p70s6k in cytoplasm (a) and nucleus            
(b) in cervical cancer before treatment with radiotherapy 
(original magnification 10×40). The white star indicates low 
expression and the black star indicates high expression.  
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(a) 
 
(b) 
 
(c) 
 
Fig. 2.  AgNOR mean (a), MIB-1 indices (b), and p53 indices 
(c) in different expressions of p70s6k in cervical cancer before 
treatment with radiotherapy. 
 
 
 
Fig. 3. Expression of p70s6k in different radiotherapy 
responses. 
The low AgNOR mean in the High 
Expression of p70s6k group is related to the 
different activity sites of p70s6k and AgNOR in the 
parts of cell cycle. AgNOR can be identified in G1, 
S, and G2 in the cell cycle, where p70s6k 
expression is observed only in G1. AgNOR will 
increase from G1 and accumulate in S, then 
decrease in G2 as observed in cervical cancer tissues 
before treatment and after 9-Gy irradiation AgNOR 
in after 9-Gy irradiation as considered in G2 phase 
and S phase before irradiation [10]. As a mitogen-
activated Ser/Thr protein kinase,  p70s6k is required 
for G1 cell cycle progression and cell proliferation 
[9]. 
The high expression of p70s6k is related to 
cell proliferation. Among actively-proliferating 
cells, the number of cells in mitosis (cycling cell) is 
higher than the number of cells in the G0 phase. 
High MIB-1 indices that appear in the High 
Expression group Table 1 are also relevant for 
studies of breast cancer and in-vitro studies using 
mammalian cells [19,20]. A high MIB-1 index 
indicates that the fraction of cancer cells growing    
is high [17]. 
 
Table 1. AgNOR mean, MIB-1 index and p53 index in different 
expression of p70s6k 
 
Biomarker 
Low Expression 
of p70s6k 
High Expression 
of p70s6k 
p value 
AgNOR Mean 6.01±1,23 (n= 8  ) 5,33±0,94  (n =13) 0.17ns 
MIB-1 Index 0,39±0.10 (n= 8  ) 0.47±0,13  (n=13) 0.16ns 
P53 Index 0.34±0.13 (n= 8 ) 0.46±0.16  (n=13) 0.11ns 
 
The high p53 index in the High Expression 
group in Table 1 was due to the presence of most 
expression of p53 in cervical cancer in mutant rather 
than in wild type, even though DNA sequencing 
analysis was not performed. An in-vitro 
investigation reported that wild type p53 can 
decrease the p70s6k expression by mTOR   pathway 
[21]. 
After treatment with radiotherapy, there were 
statistical differences in proportions of complete and 
partial radiotherapy response between the High and 
Low Expression of p70s6k groups (p=0.05).                
The high expression of p70s6k in this current study 
indicates the presence of highly proliferating cells 
that also prevent the process of apoptosis as one of 
the death mechanisms of cancer cell after receiving 
exposure of ionizing radiation in radiotherapy.            
The high portion of proliferating cells also indicate 
the cells would be more radiosensitive rather than 
radioresistant. A number of studies have focused on 
the involvement of p70s6k in influencing cellular 
responses to apoptotic stimuli [8,9]. Treatment of 
Swiss 3T3 and RAT-1 cells with etoposide and 
AgNOR Mean in Diffrerent Expression of p70s6k 
MIB-1 Index in two Mean Diffrerent Expression of p70s6k 
Level Expression of p70s6k 
PS3 Index in Different Expression of p70s6k 
Expression of p70s6k 
Expression of p70s6k in Different Radiotheraphy Response 
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staurosporine resulted in dephosphorylation and 
decreased activity of p70s6k in preventing 
apoptosis. It has also been shown that cisplatin 
inhibits the phosphorylation of p70s6k in mouse 
myoblasts [10]. Another in vitro study, using breast 
cancer cell, found that inactivation of p70s6k                
also allows the process of cell death to proceed               
and potentially sensitizes cancer cell to 
chemotherapeutic agents [22]. 
Cells in high proliferation were highly 
radiosensitive and thus giving good radiotherapy 
response, while cells in lower proliferation 
proportion will give worse radiotherapy response. 
Because in this result the observation of 
radiotherapy response was early response, we think 
that majority of cancer cell death was caused by 
irradiation rather than cisplatin in concurrent 
chemoradiotherapy. Ons study with HeLa cells 
indicate that overexpression of p70s6k protein can 
induce the process of apoptosis via Bax and Bax-
independent pathways [23]. 
The present results seems to be different from 
some reports explaining the relation between 
expression level of p70s6k and the resistance of 
some cancer cells after treatment. High expression 
of p70s6k before treatment is related with resistance 
of cancer cells or poor response toward cancer 
treatment [20].  
 
 
CONCLUSION 
The expression of p70s6k has an important 
role in cell cancer proliferation in making the cancer 
more radiosensitive or radioresistant and thus 
exhibits a potential in predicting the radiotherapy 
response. It is also as a parameter to be considered 
in patient selection before treatment. 
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